OKYO Pharma Ltd (NASDAQ:OKYO) said it has enrolled 90% of patients in its 240-patient Phase 2 evaluating topical ocular OK-101 to treat dry eye disease (DED).
Full enrollment is anticipated to be completed by the first week of September and OKYO Pharma expects to release topline data by the end of the fourth quarter of 2023.
"We are very pleased at the rapid pace of enrollment we are seeing in our ongoing Phase 2 trial of our flagship drug OK-101 to treat patients with DED,” OKYO Pharma CEO Dr. Gary Jacob said.
“This trial began in May of this year, with the first patient being randomized in June into one of the three cohorts. Having enrolled 90% of the patients in this trial is an important milestone for OKYO Pharma.”
OKYO Pharma chief scientific officer Dr. Raj Patil added that the Phase 2 trial was a crucial step in the development of OK-101, evaluating its safety, efficacy, and tolerability in a larger patient population.
“The company remains laser-focused on completing the trial, which is managed by our clinical development partner Ora Inc. a world leader in dry eye clinical research and is committed to establishing the potential of this drug to treat the many millions of people currently suffering from DED,” he said in a statement.
OKYO Pharma is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.
Its therapeutic candidate OK-101 is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie